Chronic kidney disease, defined as abnormal kidney function for more than 3 months, affects roughly 15% of the US, and approximately 40% of people with chronic kidney disease have type 2 diabetes. In the last decade, pharmacotherapies have been approved that may reduce chronic kidney disease progression and its complications. Sodium-glucose cotransporter-2 inhibitors (SGLT2Is) are recommended for diabetic kidney disease as they may reduce chronic kidney disease progression and cardiovascular events. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are recommended for those with diabetic kidney disease who have not achieved glycemic targets with metformin and SGLT2Is. Finerenone (a nonsteroidal mineralocorticoid receptor antagonist [MRA]) may reduce chronic kidney disease progression and cardiovascular events. This chapter will review the evidence for these pharmacotherapies for diabetic kidney disease.
Part of the book: Chronic Kidney Disease